

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Immunotech Biopharm Ltd**

**永泰生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6978)**

### **APPOINTMENT AND RESIGNATION OF DIRECTORS**

The Board announces that with effect from 25 August 2023:

1. Mr Wang Donghu has been appointed as a non-executive Director; and
2. Mr Si Xiaobing has resigned as a non-executive Director.

#### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that with effect from 25 August 2023, Mr Wang Donghu (王東虎) (“**Mr Wang**”) has been appointed as a non-executive Director.

The biography of Mr Wang is set out below:

#### **Mr Wang Donghu**

Mr Wang Donghu, aged 68, graduated from Renmin University of China with a master’s degree of business administration in 2003. Mr Wang has over 20 years of experience in pharmaceutical and biotechnology industries in the People’s of Republic of China (“**PRC**”). Since 2003, he has held a number of senior management positions in Boai NKY Medical Technologies Group Ltd. (“**NKY Medical**”, 博愛新開源醫療科技集團股份有限公司), a PRC based company listed on the Shenzhen Stock Exchange (“**SZSX**”) (stock code: 300109.SZ) and currently serves as a director of NKY Medical.

Save as disclosed above, as at the date of this announcement, Mr Wang (i) did not hold any positions with the Company and other members of the Group; (ii) did not hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments; (iv) does not have any other relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

There is no specific term for the appointment of Mr Wang as a non-executive Director and his appointment is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr Wang is not entitled to any Director’s fee under his appointment letter.

Pursuant to the articles of association of the Company, Mr Wang shall hold office only until the first annual general meeting of the Company after his appointment where he shall be eligible for re-election. He shall be subject to retirement by rotation thereafter and shall then be eligible for re-election.

On 6 April 2021 and 9 May 2022, SZSX issued two notices of criticism (通報批評) (“**Notices of Criticism**”) against NKY Medical and relevant individuals concerned. According to the Notices of Criticism, SZSX in view of the event that, at the material time between January 2018 to June 2019, NKY Medical has provided loans, financial assistance and capitals to associate companies of the then chairman of NKY Medical (the “**Relevant Financial Assistance**”) without timely disclosure of such information in accordance with the relevant listing rules of SZSX. The Notices of Criticism was expressed by SZSX against the then director and senior management of NKY Medical (which included Mr Wang as the then general manager of NKY Medical). Also, pursuant to the Notices of Criticism, SZSX would file the said disciplinary action in the integrity database of listed companies (上市公司誠信檔案). On 5 January 2022, Henan Supervision Bureau of China Securities Regulatory Commission (中國證券監督管理委員會河南監管局) (the “**Local CSRC**”) issued a decision on the administrative regulatory measures of (行政監管措施決定書) (the “**Local CSRC Decision**”) in view of the event that, at the material time between January 2018 to June 2019, NKY Medical failed to disclose the Relevant Financial Assistance and the relevant asset reorganisation transaction in a timely manner. The Local CSRC issued a warning notice (警示函) for breach of PRC securities laws and regulations to NKY Medical, its current and then directors and senior management (which included Mr Wang as the then general manager of NKY Medical); and filed the matter in the integrity of database of securities and futures market (證券期貨市場誠信檔案). As confirmed by Mr Wang, the breach was due to inadvertent oversight of the relevant rules and regulations, he had no involvement in any of the transactions in respect of the Relevant Financial Assistance, that did not involve in any fraud, theft, other type of dishonesty, and other matters in relation concerning the character and integrity issue on the part of Mr Wang. Save and except the Notices of Criticism and the Local CSRC Decision, to date, he has neither been subject to any other disciplinary actions

imposed by any regulatory or governmental authority or professional body, nor disqualified from holding, or deemed unfit to hold, the position of director of an enterprise. Subsequent to the event, Mr Wang has been appointed as one of the director of NKY Medical since December 2021. After having the incident as stated in the Notices of Criticism and the Local CSRC Decision and taking into account (i) the facts as stated; (ii) Mr Wang’s undertaking to strengthen his familiarity of with the relevant listing rules and securities laws and regulations and (iii) the ample expertise, skills and experience of Mr Wang, the Board and the nomination committee of the Company considered that Mr Wang is suitable to act as a non-executive Director.

Save as disclosed above, Mr Wang confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company (the “Shareholders”) in connection with his appointment as a non-executive Director.

The Board would like to express its warmest welcome to Mr Wang for joining the Board.

#### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board further announces that Mr Si Xiaobing (“Mr Si”) has resigned from his position as a non-executive Director with effect from 25 August 2023, due to his other personal commitments. Mr Si has confirmed that he has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Mr Si for his valuable contribution to the Company during his tenure of service.

By order of the Board  
**Immunotech Biopharm Ltd**  
**Tan Zheng**  
*Chairman and executive Director*

Hong Kong, 25 August 2023

*As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Director, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.*